Inflammatory and neuroendocrine biomarkers of prognosis after ischemic stroke

References

• Lloyd-Jones D, Adams RJ, Brown TM et al. Heart Disease and Stroke Statistics – 2010 Update: a report from the American Heart Association. Circulation121(7), e46–e215 (2010).
   PubMed Web of Science ®Google Scholar
• Maas MB, Furie KL. Molecular biomarkers in stroke diagnosis and prognosis. Biomark. Med.3(4), 363–383 (2009).
   PubMed Web of Science ®Google Scholar
• NIH-FDA Conference: Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications. Abstracts. Dis. Markers14(4), 187–334 (1998).
   PubMedGoogle Scholar
• Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci.22(9), 391–397 (1999).
   PubMed Web of Science ®Google Scholar
• Chamorro A, Urra X, Planas AM. Infection after acute ischemic stroke: a manifestation of brain-induced immunodepression. Stroke38(3), 1097–1103 (2007).
   PubMed Web of Science ®Google Scholar
• Shoja MM, Tubbs RS, Shokouhi G, Loukas M, Ghabili K, Ansarin K. The potential role of carbon dioxide in the neuroimmunoendocrine changes following cerebral ischemia. Life Sci.83(11–12), 381–387 (2008).
   PubMedGoogle Scholar
• Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron67(2), 181–198 (2010).
   PubMed Web of Science ®Google Scholar
• DeVries AC, Joh HD, Bernard O et al. Social stress exacerbates stroke outcome by suppressing Bcl-2 expression. Proc. Natl Acad. Sci. USA98(20), 11824–11828 (2001).
   PubMed Web of Science ®Google Scholar
• El Husseini N, Laskowitz DT. Clinical application of blood biomarkers in cerebrovascular disease. Expert Rev. Neurother.10(2), 189–203 (2010).
   PubMed Web of Science ®Google Scholar
• Stamova B, Xu H, Jickling G et al. Gene expression profiling of blood for the prediction of ischemic stroke. Stroke41(10), 2171–2177 (2010).
   PubMed Web of Science ®Google Scholar
• Tang Y, Xu H, Du X et al. Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J. Cereb. Blood Flow Metab.26(8), 1089–1102 (2006).
   PubMed Web of Science ®Google Scholar
• Laterza OF, Modur VR, Crimmins DL et al. Identification of novel brain biomarkers. Clin. Chem.52(9), 1713–1721 (2006).
   PubMed Web of Science ®Google Scholar
• Xu H, Tang Y, Liu DZ et al. Gene expression in peripheral blood differs after cardioembolic compared with large-vessel atherosclerotic stroke: biomarkers for the etiology of ischemic stroke. J. Cereb. Blood Flow Metab.28(7), 1320–1328 (2008).
   PubMed Web of Science ®Google Scholar
• Dave JR, Williams AJ, Yao C, Lu XC, Tortella FC. Modeling cerebral ischemia in neuroproteomics. Methods Mol. Biol.566, 25–40 (2009).
   PubMedGoogle Scholar
• Allard L, Burkhard PR, Lescuyer P et al. PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin. Chem.51(11), 2043–2051 (2005).
   PubMed Web of Science ®Google Scholar
• Cuadrado E, Rosell A, Penalba A et al. Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: a combined laser microdissection and protein array study. J. Proteome Res.8(6), 3191–3197 (2009).
   PubMedGoogle Scholar
• Koizumi S, Yamamoto S, Hayasaka T et al. Imaging mass spectrometry revealed the production of lyso-phosphatidylcholine in the injured ischemic rat brain. Neuroscience168(1), 219–225 (2010).
   PubMed Web of Science ®Google Scholar
• Endres M, Engelhardt B, Koistinaho J et al. Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc. Dis.25(3), 268–278 (2008).
   PubMedGoogle Scholar
• Priller J, Flugel A, Wehner T et al. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat. Med.7(12), 1356–1361 (2001).
   PubMed Web of Science ®Google Scholar
• Eglitis MA, Mezey E. Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc. Natl Acad. Sci. USA94(8), 4080–4085 (1997).
   PubMed Web of Science ®Google Scholar
• Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl Acad. Sci. USA96(23), 13496–13500 (1999).
   PubMed Web of Science ®Google Scholar
• Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat. Rev. Immunol.5(8), 629–640 (2005).
   PubMed Web of Science ®Google Scholar
• Emsley HC, Smith CJ, Georgiou RF et al. A randomised Phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatry76(10), 1366–1372 (2005).
   PubMed Web of Science ®Google Scholar
• Kerschensteiner M, Gallmeier E, Behrens L et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J. Exp. Med.189(5), 865–870 (1999).
   PubMed Web of Science ®Google Scholar
• Emsley HC, Smith CJ, Tyrrell PJ, Hopkins SJ. Inflammation in acute ischemic stroke and its relevance to stroke critical care. Neurocrit. Care9(1), 125–138 (2008).
   PubMed Web of Science ®Google Scholar
• Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron67(2), 181–198 (2010).
   PubMed Web of Science ®Google Scholar
• Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J. Neuroimmunol.184(1–2), 53–68 (2007).
   PubMed Web of Science ®Google Scholar
• Shohami E, Ginis I, Hallenbeck JM. Dual role of tumor necrosis factor α in brain injury. Cytokine Growth Factor Rev.10(2), 119–130 (1999).
   PubMed Web of Science ®Google Scholar
• Protopsaltis J, Kokkoris S, Korantzopoulos P et al. Prediction of long-term functional outcome in patients with acute ischemic non-embolic stroke. Atherosclerosis203(1), 228–235 (2009).
   PubMedGoogle Scholar
• Hopkins SJ. The pathophysiological role of cytokines. Leg. Med. (Tokyo)5(Suppl. 1), S45–S57 (2003).
   PubMedGoogle Scholar
• Castellanos M, Sobrino T, Pedraza S et al. High plasma glutamate concentrations are associated with infarct growth in acute ischemic stroke. Neurology71(23), 1862–1868 (2008).
   PubMed Web of Science ®Google Scholar
• Smith CJ, Emsley HC, Gavin CM et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol.4, 2 (2004).
   PubMed Web of Science ®Google Scholar
• Vila N, Castillo J, Davalos A, Esteve A, Planas AM, Chamorro A. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke34(3), 671–675 (2003).
   PubMed Web of Science ®Google Scholar
• Waje-Andreassen U, Krakenes J, Ulvestad E et al. IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol. Scand.111(6), 360–365 (2005).
   PubMed Web of Science ®Google Scholar
• Sotgiu S, Zanda B, Marchetti B et al. Inflammatory biomarkers in blood of patients with acute brain ischemia. Eur. J. Neurol.13(5), 505–513 (2006).
   PubMed Web of Science ®Google Scholar
• Basic Kes V, Simundic AM, Nikolac N, Topic E, Demarin V. Pro-inflammatory and anti-inflammatory cytokines in acute ischemic stroke and their relation to early neurological deficit and stroke outcome. Clin. Biochem.41(16–17), 1330–1334 (2008).
   PubMed Web of Science ®Google Scholar
• Blanco M, Castellanos M, Rodriguez-Yanez M et al. High blood pressure and inflammation are associated with poor prognosis in lacunar infarctions. Cerebrovasc. Dis.22(2–3), 123–129 (2006).
   PubMedGoogle Scholar
• Rallidis LS, Vikelis M, Panagiotakos DB et al. Inflammatory markers and in-hospital mortality in acute ischaemic stroke. Atherosclerosis189(1), 193–197 (2006).
   PubMed Web of Science ®Google Scholar
• Whiteley W, Jackson C, Lewis S et al. Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med.6(9), e1000145 (2009).
   PubMed Web of Science ®Google Scholar
• Emsley HC, Smith CJ, Tyrrell PJ, Hopkins SJ. Inflammation in acute ischemic stroke and its relevance to stroke critical care. Neurocrit. Care9(1), 125–138 (2008).
   PubMed Web of Science ®Google Scholar
• Castillo J, Alvarez-Sabin J, Martinez-Vila E, Montaner J, Sobrino T, Vivancos J. Inflammation markers and prediction of post-stroke vascular disease recurrence: the MITICO study. J. Neurol.256(2), 217–224 (2009).
   PubMed Web of Science ®Google Scholar
• Whiteley W, Jackson C, Lewis S et al. Association of circulating inflammatory markers with recurrent vascular events after stroke. A prospective cohort study. StrokeDOI: 10.1161/strokeaha.110.588954 (2010) (Epub ahead of print.)
   PubMedGoogle Scholar
• Welsh P, Lowe G, Chalmers J et al. Associations of proinflammatory cytokines with the risk of recurrent stroke. Stroke39(8), 2226–2230 (2008).
   PubMed Web of Science ®Google Scholar
• Liu T, Clark RK, McDonnell PC et al. Tumor necrosis factor-α expression in ischemic neurons. Stroke25(7), 1481–1488 (1994).
   PubMed Web of Science ®Google Scholar
• Murakami Y, Saito K, Hara A et al. Increases in tumor necrosis factor-α following transient global cerebral ischemia do not contribute to neuron death in mouse hippocampus. J. Neurochem.93(6), 1616–1622 (2005).
   PubMedGoogle Scholar
• Castellanos M, Leira R, Serena J et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke35(7), 1671–1676 (2004).
   PubMed Web of Science ®Google Scholar
• Rosell A, Alvarez-Sabin J, Arenillas JF et al. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke36(7), 1415–1420 (2005).
   PubMed Web of Science ®Google Scholar
• Castellanos M, Castillo J, Garcia MM et al. Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke33(4), 982–987 (2002).
   PubMed Web of Science ®Google Scholar
• Licata G, Tuttolomondo A, Di Raimondo D, Corrao S, Di Sciacca R, Pinto A. Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke. Thromb. Haemost.101(5), 929–937 (2009).
   PubMed Web of Science ®Google Scholar
• Elkind MS, Cheng J, Boden-Albala B et al. Tumor necrosis factor receptor levels are associated with carotid atherosclerosis. Stroke33(1), 31–37 (2002).
   PubMedGoogle Scholar
• Blann AD, McCollum CN. Increased levels of soluble tumor necrosis factor receptors in atherosclerosis: no clear relationship with levels of tumor necrosis factor. Inflammation22(5), 483–491 (1998).
   PubMedGoogle Scholar
• Valgimigli M, Ceconi C, Malagutti P et al. Tumor necrosis factor-α receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. Circulation111(7), 863–870 (2005).
   PubMed Web of Science ®Google Scholar
• Blann AD, Ridker PM, Lip GY. Inflammation, cell adhesion molecules, and stroke: tools in pathophysiology and epidemiology? Stroke33(9), 2141–2143 (2002).
   PubMed Web of Science ®Google Scholar
• Boos CJ, Lip GY, Blann AD. Circulating endothelial cells in cardiovascular disease. J. Am. Coll. Cardiol.48(8), 1538–1547 (2006).
   PubMed Web of Science ®Google Scholar
• Nadar SK, Lip GY, Lee KW, Blann AD. Circulating endothelial cells in acute ischaemic stroke. Thromb. Haemost.94(4), 707–712 (2005).
   PubMed Web of Science ®Google Scholar
• Makin AJ, Blann AD, Chung NA, Silverman SH, Lip GY. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor. Eur. Heart J.25(5), 371–376 (2004).
   PubMedGoogle Scholar
• Tuttolomondo A, Pinto A, Corrao S et al. Immuno-inflammatory and thrombotic/fibrinolytic variables associated with acute ischemic stroke diagnosis. Atherosclerosis203(2), 503–508 (2009).
   PubMed Web of Science ®Google Scholar
• Licata G, Tuttolomondo A, Corrao S et al. Immunoinflammatory activation during the acute phase of lacunar and non-lacunar ischemic stroke: association with time of onset and diabetic state. Int. J. Immunopathol. Pharmacol.19(3), 639–646 (2006).
   PubMed Web of Science ®Google Scholar
• Tan KT, Blann AD. To stroke or not to stroke: is ICAM-1 or CRP the answer? Neurology60(12), 1884–1885 (2003).
   PubMed Web of Science ®Google Scholar
• Mocco J, Choudhri TF, Mack WJ et al. Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis. Neurosurgery48(4), 718–721; discussion 721–712 (2001).
   PubMed Web of Science ®Google Scholar
• Uno M, Kitazato KT, Nishi K, Itabe H, Nagahiro S. Raised plasma oxidised LDL in acute cerebral infarction. J. Neurol. Neurosurg. Psychiatry74(3), 312–316 (2003).
   PubMed Web of Science ®Google Scholar
• El Husseini N, Laskowitz DT. Clinical application of blood biomarkers in cerebrovascular disease. Expert Rev. Neurother.10(2), 189–203 (2010).
   PubMed Web of Science ®Google Scholar
• Qizilbash N, Jones L, Warlow C, Mann J. Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes. BMJ303(6803), 605–609 (1991).
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Howard SC, Power DA et al. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke35(10), 2300–2305 (2004).
   PubMedGoogle Scholar
• Ballantyne CM, Nambi V. Markers of inflammation and their clinical significance. Atheroscler. Suppl.6(2), 21–29 (2005).
   PubMed Web of Science ®Google Scholar
• Tanne D, Macko RF, Lin Y, Tilley BC, Levine SR. Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke37(7), 1798–1804 (2006).
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Singh P. Is plasma fibrinogen useful in evaluating ischemic stroke patients?: why, how, and when. Stroke40(5), 1549–1552 (2009).
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke32(1), 133–138 (2001).
   PubMed Web of Science ®Google Scholar
• del Zoppo GJ, Levy DE, Wasiewski WW et al. Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke40(5), 1687–1691 (2009).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Conejero R, Fernandez-Cadenas I, Iniesta JA et al. Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke37(9), 2288–2293 (2006).
   PubMed Web of Science ®Google Scholar
• Tuttolomondo A, Di Sciacca R, Di Raimondo D et al. Plasma levels of inflammatory and thrombotic/fibrinolytic markers in acute ischemic strokes: relationship with TOAST subtype, outcome and infarct site. J. Neuroimmunol.215(1-2), 84–89 (2009).
   PubMed Web of Science ®Google Scholar
• Marti-Fabregas J, Borrell M, Cocho D et al. Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA. Neurology65(3), 366–370 (2005).
   PubMedGoogle Scholar
• Haapaniemi E, Tatlisumak T. Is D-dimer helpful in evaluating stroke patients? A systematic review. Acta Neurol. Scand.119(3), 141–150 (2009).
   PubMed Web of Science ®Google Scholar
• Feinberg WM, Erickson LP, Bruck D, Kittelson J. Hemostatic markers in acute ischemic stroke. Association with stroke type, severity, and outcome. Stroke27(8), 1296–1300 (1996).
   PubMedGoogle Scholar
• Welsh P, Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ. Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc. Dis.27(3), 247–253 (2009).
   PubMed Web of Science ®Google Scholar
• Kang DW, Yoo SH, Chun S et al. Inflammatory and hemostatic biomarkers associated with early recurrent ischemic lesions in acute ischemic stroke. Stroke40(5), 1653–1658 (2009).
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Papa F. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke33(7), 1763–1771 (2002).
   PubMed Web of Science ®Google Scholar
• Takano K, Yamaguchi T, Kato H, Omae T. Activation of coagulation in acute cardioembolic stroke. Stroke22(1), 12–16 (1991).
   PubMedGoogle Scholar
• Audebert HJ, Pellkofer TS, Wimmer ML, Haberl RL. Progression in lacunar stroke is related to elevated acute phase parameters. Eur. Neurol.51(3), 125–131 (2004).
   PubMedGoogle Scholar
• Woodward M, Lowe GD, Campbell DJ et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke36(10), 2143–2147 (2005).
   PubMed Web of Science ®Google Scholar
• Bruno A, McConnell JP, Cohen SN et al. Plasma thrombosis markers following cerebral infarction in African Americans. Thromb. Res.115(1–2), 73–77 (2005).
   PubMedGoogle Scholar
• Carter AM, Catto AJ, Mansfield MW, Bamford JM, Grant PJ. Predictive variables for mortality after acute ischemic stroke. Stroke38(6), 1873–1880 (2007).
   PubMed Web of Science ®Google Scholar
• Catto AJ, Carter AM, Barrett JH, Bamford J, Rice PJ, Grant PJ. von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality. Thromb. Haemost.77(6), 1104–1108 (1997).
   PubMed Web of Science ®Google Scholar
• Sato M, Suzuki A, Nagata K, Uchiyama S. Increased von Willebrand factor in acute stroke patients with atrial fibrillation. J. Stroke Cerebrovasc. Dis.15(1), 1–7 (2006).
   PubMedGoogle Scholar
• Ribo M, Montaner J, Molina CA et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke35(9), 2123–2127 (2004).
   PubMed Web of Science ®Google Scholar
• Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Alvarez-Sabin J. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb. Haemost.91(6), 1146–1151 (2004).
   PubMed Web of Science ®Google Scholar
• Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M et al. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. J. Thromb. Haemost.5(9), 1862–1868 (2007).
   PubMedGoogle Scholar
• Montaner J, Alvarez-Sabin J, Molina CA et al. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke32(12), 2762–2767 (2001).
   PubMed Web of Science ®Google Scholar
• Montaner J, Rovira A, Molina CA et al. Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. J. Cereb. Blood Flow Metab.23(12), 1403–1407 (2003).
   PubMed Web of Science ®Google Scholar
• Kelly PJ, Morrow JD, Ning M et al. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke. The Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke39, 100–104 (2008).
   PubMed Web of Science ®Google Scholar
• Montaner J, Molina CA, Monasterio J et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation107(4), 598–603 (2003).
   PubMed Web of Science ®Google Scholar
• Ning M, Furie KL, Koroshetz WJ et al. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology66(10), 1550–1555 (2006).
   PubMed Web of Science ®Google Scholar
• Rosell A, Cuadrado E, Ortega-Aznar A, Hernandez-Guillamon M, Lo EH, Montaner J. MMP-9-positive neutrophil infiltration is associated to blood–brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke39(4), 1121–1126 (2008).
   PubMed Web of Science ®Google Scholar
• Kuta AE, Baum LL. C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J. Exp. Med.164(1), 321–326 (1986).
   PubMed Web of Science ®Google Scholar
• Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am. J. Pathol.158(3), 1039–1051 (2001).
   PubMed Web of Science ®Google Scholar
• Devaraj S, O’Keefe G, Jialal I. Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J. Clin. Endocrinol. Metab.90(8), 4549–4554 (2005).
   PubMed Web of Science ®Google Scholar
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J. Clin. Invest.111(12), 1805–1812 (2003).
   PubMed Web of Science ®Google Scholar
• Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: a critical review. J. Intern. Med.264(4), 295–314 (2008).
   PubMed Web of Science ®Google Scholar
• Torzewski J, Torzewski M, Bowyer DE et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler. Thromb. Vasc. Biol.18(9), 1386–1392 (1998).
   PubMed Web of Science ®Google Scholar
• Volanakis JE, Kaplan MH. Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J. Immunol.113(1), 9–17 (1974).
   PubMed Web of Science ®Google Scholar
• Bisoendial RJ, Kastelein JJ, Levels JH et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ. Res.96(7), 714–716 (2005).
   PubMed Web of Science ®Google Scholar
• Paffen E, DeMaat MP. C-reactive protein in atherosclerosis: a causal factor? Cardiovasc. Res.71(1), 30–39 (2006).
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Schwaninger M, Cappelli R et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke36(6), 1316–1329 (2005).
   PubMed Web of Science ®Google Scholar
• Kuhlmann CR, Librizzi L, Closhen D et al. Mechanisms of C-reactive protein-induced blood–brain barrier disruption. Stroke40(4), 1458–1466 (2009).
   PubMedGoogle Scholar
• Emsley HC, Smith CJ, Gavin CM et al. An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J. Neuroimmunol.139(1–2), 93–101 (2003).
   PubMed Web of Science ®Google Scholar
• Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch. Intern. Med.166(19), 2073–2080 (2006).
   PubMed Web of Science ®Google Scholar
• Shantikumar S, Grant PJ, Catto AJ, Bamford JM, Carter AM. Elevated C-reactive protein and long-term mortality after ischaemic stroke: relationship with markers of endothelial cell and platelet activation. Stroke40(3), 977–979 (2009).
   PubMed Web of Science ®Google Scholar
• den Hertog HM, van Rossum JA, van der Worp HB et al. C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death. J. Neurol. DOI: 10.1007/s00415-009-5228-x. (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stroke30(5), 981–985 (1999).
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke32(4), 917–924 (2001).
   PubMed Web of Science ®Google Scholar
• Winbeck K, Poppert H, Etgen T, Conrad B, Sander D. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke33(10), 2459–2464 (2002).
   PubMed Web of Science ®Google Scholar
• Montaner J, Fernandez-Cadenas I, Molina CA et al. Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke37(5), 1205–1210 (2006).
   PubMed Web of Science ®Google Scholar
• Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation107(3), 499–511 (2003).
   PubMed Web of Science ®Google Scholar
• Elkind MS, Luna JM, Coffey CS et al. The Levels of Inflammatory Markers in the Treatment of Stroke study (LIMITS): inflammatory biomarkers as risk predictors after lacunar stroke. Int. J. Stroke5(2), 117–125 (2010).
   PubMedGoogle Scholar
• Packard CJ, O’Reilly DS, Caslake MJ et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med.343(16), 1148–1155 (2000).
   PubMed Web of Science ®Google Scholar
• MacPhee CH, Moores KE, Boyd HF et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem. J.338(Pt 2), 479–487 (1999).
   PubMed Web of Science ®Google Scholar
• White H. Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes. Curr. Opin. Cardiol.25(4), 299–301 (2010).
   PubMedGoogle Scholar
• Ballantyne CM, Hoogeveen RC, Bang H et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch. Intern. Med.165(21), 2479–2484 (2005).
   PubMedGoogle Scholar
• Oei HH, van der Meer IM, Hofman A et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation111(5), 570–575 (2005).
   PubMed Web of Science ®Google Scholar
• Thompson A, Gao P, Orfei L et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet375(9725), 1536–1544 (2010).
   PubMed Web of Science ®Google Scholar
• Nambi V, Hoogeveen RC, Chambless L et al. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke40(2), 376–381 (2009).
   PubMed Web of Science ®Google Scholar
• Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc Dis27(1), 42–50 (2009).
   PubMed Web of Science ®Google Scholar
• Cucchiara BL, Messe SR, Sansing L et al. Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke40(7), 2332–2336 (2009).
   PubMed Web of Science ®Google Scholar
• McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol. Rev.87(3), 873–904 (2007).
   PubMed Web of Science ®Google Scholar
• Pervanidou P, Chrousos GP. Neuroendocrinology of post-traumatic stress disorder. Prog. Brain Res.182, 149–160 (2010).
   PubMed Web of Science ®Google Scholar
• Ay H, Koroshetz WJ, Benner T et al. Neuroanatomic correlates of stroke-related myocardial injury. Neurology66(9), 1325–1329 (2006).
   PubMed Web of Science ®Google Scholar
• Chamorro A, Amaro S, Vargas M et al. Catecholamines, infection, and death in acute ischemic stroke. J. Neurol. Sci.252(1), 29–35 (2007).
   PubMed Web of Science ®Google Scholar
• Meyer S, Strittmatter M, Fischer C, Georg T, Schmitz B. Lateralization in autonomic dysfunction in ischemic stroke involving the insular cortex. Neuroreport15(2), 357–361 (2004).
   PubMed Web of Science ®Google Scholar
• Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B. Prognostic relevance of pathological sympathetic activation after acute thromboembolic stroke. Neurology57(5), 833–838 (2001).
   PubMed Web of Science ®Google Scholar
• Urra X, Cervera A, Obach V, Climent N, Planas AM, Chamorro A. Monocytes are major players in the prognosis and risk of infection after acute stroke. Stroke40(4), 1262–1268 (2009).
   PubMed Web of Science ®Google Scholar
• Klehmet J, Harms H, Richter M et al. Stroke-induced immunodepression and post-stroke infections: lessons from the preventive antibacterial therapy in stroke trial. Neuroscience158(3), 1184–1193 (2009).
   PubMed Web of Science ®Google Scholar
• Hjemdahl P. Plasma catecholamines – analytical challenges and physiological limitations. Baillieres Clin. Endocrinol. Metab.7(2), 307–353 (1993).
   PubMed Web of Science ®Google Scholar
• Giuffrida R, Bellomo M, Polizzi G, Malatino LS. Ischemia-induced changes in the immunoreactivity for endothelin and other vasoactive peptides in the brain of the Mongolian gerbil. J. Cardiovasc. Pharmacol.20(12 Suppl.), S41–S44 (1992).
   Google Scholar
• Nogami M, Shiga J, Takatsu A, Endo N, Ishiyama I. Immunohistochemistry of atrial natriuretic peptide in brain infarction. Histochem. J.33(2), 87–90 (2001).
   PubMedGoogle Scholar
• Nakagawa K, Yamaguchi T, Seida M et al. Plasma concentrations of brain natriuretic peptide in patients with acute ischemic stroke. Cerebrovasc. Dis.19(3), 157–164 (2005).
   PubMed Web of Science ®Google Scholar
• Makikallio AM, Makikallio TH, Korpelainen JT et al. Natriuretic peptides and mortality after stroke. Stroke36(5), 1016–1020 (2005).
   PubMed Web of Science ®Google Scholar
• Etgen T, Baum H, Sander K, Sander D. Cardiac troponins and N-terminal pro-brain natriuretic peptide in acute ischemic stroke do not relate to clinical prognosis. Stroke36(2), 270–275 (2005).
   PubMed Web of Science ®Google Scholar
• Giannakoulas G, Hatzitolios A, Karvounis H et al. N-terminal pro-brain natriuretic peptide levels are elevated in patients with acute ischemic stroke. Angiology56(6), 723–730 (2005).
   PubMedGoogle Scholar
• Rubattu S, Stanzione R, Di Angelantonio E et al. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke35(4), 814–818 (2004).
   PubMed Web of Science ®Google Scholar
• Ala-Kopsala M, Magga J, Peuhkurinen K et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin. Chem.50(9), 1576–1588 (2004).
   PubMed Web of Science ®Google Scholar
• Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin. Chem.50(1), 234–236 (2004).
   PubMed Web of Science ®Google Scholar
• Omland T, Persson A, Ng L et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation106(23), 2913–2918 (2002).
   PubMed Web of Science ®Google Scholar
• Omland T, de Lemos JA, Morrow DA et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am. J. Cardiol.89(4), 463–465 (2002).
   PubMed Web of Science ®Google Scholar
• Gegenhuber A, Mueller T, Dieplinger B, Poelz W, Pacher R, Haltmayer M. B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure. Clin. Chim. Acta370(1–2), 174–179 (2006).
   PubMedGoogle Scholar
• Gegenhuber A, Struck J, Poelz W et al. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clin. Chem.52(5), 827–831 (2006).
   PubMed Web of Science ®Google Scholar
• Christ M, Thuerlimann A, Laule K et al. Long-term prognostic value of B-type natriuretic peptide in cardiac and non-cardiac causes of acute dyspnoea. Eur. J. Clin. Invest.37(11), 834–841 (2007).
   PubMedGoogle Scholar
• Katan M, Fluri F, Schuetz P et al. Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke J. Am. Coll. Cardiol.56(13), 1045–1053 (2010).
   PubMed Web of Science ®Google Scholar
• Whiteley W, Rumley A, Sattar N et al. POS11 blood markers and poor outcome after acute cerebrovascular disease: a prospective cohort study. J. Neurol. Neurosurg. Psychiatry81(11), e70 (2010).
   PubMedGoogle Scholar
• Wang TJ, Gona P, Larson MG et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med.355(25), 2631–2639 (2006).
   PubMed Web of Science ®Google Scholar
• Montaner J, Perea-Gainza M, Delgado P et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke39(8), 2280–2287 (2008).
   PubMed Web of Science ®Google Scholar
• Yukiiri K, Hosomi N, Naya T et al. Plasma brain natriuretic peptide as a surrogate marker for cardioembolic stroke. BMC Neurol.8, 45 (2008).
   PubMedGoogle Scholar
• Chrousos GP. The hypothalamic–pituitary–adrenal axis and immune-mediated inflammation. N. Engl. J. Med.332(20), 1351–1362 (1995).
   PubMed Web of Science ®Google Scholar
• Charmandari E, Tsigos C, Chrousos G. Endocrinology of the stress response. Annu. Rev. Physiol.67, 259–284 (2005).
   PubMed Web of Science ®Google Scholar
• Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA267(9), 1244–1252 (1992).
   PubMed Web of Science ®Google Scholar
• Volpi S, Rabadan-Diehl C, Aguilera G. Vasopressinergic regulation of the hypothalamic pituitary adrenal axis and stress adaptation. Stress7(2), 75–83 (2004).
   PubMed Web of Science ®Google Scholar
• Aguilera G, Subburaju S, Young S, Chen J. The parvocellular vasopressinergic system and responsiveness of the hypothalamic pituitary adrenal axis during chronic stress. Prog. Brain Res.170, 29–39 (2008).
   PubMed Web of Science ®Google Scholar
• Tanoue A, Ito S, Honda K et al. The vasopressin V1b receptor critically regulates hypothalamic–pituitary–adrenal axis activity under both stress and resting conditions. J. Clin Invest113(2), 302–309 (2004).
   PubMed Web of Science ®Google Scholar
• Turnbull AV, Rivier CL. Regulation of the hypothalamic–pituitary–adrenal axis by cytokines: actions and mechanisms of action. Physiol. Rev.79(1), 1–71 (1999).
   PubMed Web of Science ®Google Scholar
• Johansson A, Olsson T, Carlberg B, Karlsson K, Fagerlund M. Hypercortisolism after stroke – partly cytokine-mediated? J. Neurol. Sci.147(1), 43–47 (1997).
   PubMed Web of Science ®Google Scholar
• Szczudlik A, Dziedzic T, Bartus S, Slowik A, Kieltyka A. Serum interleukin-6 predicts cortisol release in acute stroke patients. J. Endocrinol. Invest.27(1), 37–41 (2004).
   PubMed Web of Science ®Google Scholar
• Wilckens T, De Rijk R. Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol. Today18(9), 418–424 (1997).
   PubMedGoogle Scholar
• Besedovsky H, del Rey A, Sorkin E, Dinarello CA. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science233(4764), 652–654 (1986).
   PubMed Web of Science ®Google Scholar
• Fassbender K, Schmidt R, Mossner R, Daffertshofer M, Hennerici M. Pattern of activation of the hypothalamic–pituitary–adrenal axis in acute stroke. Relation to acute confusional state, extent of brain damage, and clinical outcome. Stroke25(6), 1105–1108 (1994).
   PubMed Web of Science ®Google Scholar
• Olsson T, Marklund N, Gustafson Y, Nasman B. Abnormalities at different levels of the hypothalamic–pituitary–adrenocortical axis early after stroke. Stroke23(11), 1573–1576 (1992).
   PubMed Web of Science ®Google Scholar
• Olsson T. Urinary free cortisol excretion shortly after ischaemic stroke. J. Intern. Med.228(2), 177–181 (1990).
   PubMed Web of Science ®Google Scholar
• Christensen H, Boysen G, Johannesen HH. Serum-cortisol reflects severity and mortality in acute stroke. J. Neurol. Sci.217(2), 175–180 (2004).
   PubMed Web of Science ®Google Scholar
• O’Neill PA, Davies I, Fullerton KJ, Bennett D. Stress hormone and blood glucose response following acute stroke in the elderly. Stroke22(7), 842–847 (1991).
   PubMed Web of Science ®Google Scholar
• Murros K, Fogelholm R, Kettunen S, Vuorela AL, Valve J. Blood glucose, glycosylated haemoglobin, and outcome of ischemic brain infarction. J. Neurol. Sci.111(1), 59–64 (1992).
   PubMedGoogle Scholar
• Slowik A, Turaj W, Pankiewicz J, Dziedzic T, Szermer P, Szczudlik A. Hypercortisolemia in acute stroke is related to the inflammatory response. J. Neurol. Sci.196(1–2), 27–32 (2002).
   PubMed Web of Science ®Google Scholar
• Anne M, Juha K, Timo M et al. Neurohormonal activation in ischemic stroke: effects of acute phase disturbances on long-term mortality. Curr. Neurovasc. Res.4(3), 170–175 (2007).
   PubMedGoogle Scholar
• Neidert S, Katan M, Schuetz P et al. Anterior pituitary-axis hormones and outcome in acute ischemic stroke. J. Int. Med. DOI: 10.1111/j.1365-2796.2010.02327.x. (2010) (Epub ahead of print).
   Google Scholar
• Sapolsky RM, Pulsinelli WA. Glucocorticoids potentiate ischemic injury to neurons: therapeutic implications. Science229(4720), 1397–1400 (1985).
   PubMed Web of Science ®Google Scholar
• Krugers HJ, Maslam S, Korf J, Joels M, Holsboer F. The corticosterone synthesis inhibitor metyrapone prevents hypoxia/ischemia-induced loss of synaptic function in the rat hippocampus. Stroke31(5), 1162–1172 (2000).
   PubMed Web of Science ®Google Scholar
• Seckl JR, Olsson T. Glucocorticoid hypersecretion and the age-impaired hippocampus: cause or effect? J. Endocrinol.145(2), 201–211 (1995).
   PubMedGoogle Scholar
• Feibel JH, Hardy PM, Campbell RG, Goldstein MN, Joynt RJ. Prognostic value of the stress response following stroke. JAMA238(13), 1374–1376 (1977).
   PubMed Web of Science ®Google Scholar
• Samuels MA. The brain–heart connection. Circulation116(1), 77–84 (2007).
   PubMed Web of Science ®Google Scholar
• Petraglia F, Genazzani AD, Aguzzoli L et al. Pulsatile fluctuations of plasma-gonadotropin-releasing hormone and corticotropin-releasing factor levels in healthy pregnant women. Acta Obstet. Gynecol. Scand.73(4), 284–289 (1994).
   PubMed Web of Science ®Google Scholar
• Evans MJ, Livesey JH, Ellis MJ, Yandle TG. Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones. Clin. Biochem.34(2), 107–112 (2001).
   PubMed Web of Science ®Google Scholar
• Latendresse G, Ruiz RJ. Bioassay research methodology: measuring CRH in pregnancy. Biol. Res. Nurs.10(1), 54–62 (2008).
   PubMedGoogle Scholar
• Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides26(12), 2500–2504 (2005).
   PubMed Web of Science ®Google Scholar
• Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides26(12), 2500–2504 (2005).
   PubMed Web of Science ®Google Scholar
• Katan M, Fluri F, Morgenthaler NG et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann. Neurol.66(6), 799–808 (2009).
   PubMed Web of Science ®Google Scholar
• Urwyler SA, Schuetz P, Fluri F et al. Prognostic value of copeptin: one-year outcome in patients with acute stroke. Stroke41(7), 1564–1567 (2010).
   PubMed Web of Science ®Google Scholar
• Katan M, Nigro N, Fluri F et al. Stress hormones predict cerebrovascular re-events after transient ischemic attacks. Neurology DOI: 10.1212/WNL.0b013e31820b75e6 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Darzy KH, Dixit KC, Shalet SM, Morgenthaler NG, Brabant G. Circadian secretion pattern of copeptin, the C-terminal vasopressin precursor fragment. Clin. Chem.56(7), 1190–1191 (2010).
   PubMed Web of Science ®Google Scholar
• Katan M, Morgenthaler N, Widmer I et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol. Lett.29(3), 341–346 (2008).
   PubMed Web of Science ®Google Scholar
• De Marchis GM, Katan M, Weck A et al. Validation of copeptin as prognostic marker in ischemic stroke. Presented at: Twentieth Meeting of the European Neurological Society. Berlin, Germany, Symposia and Free Communications, 19–23 June, 2010.
   Google Scholar
• Vogelbaum MA, Masaryk T, Mazzone P et al. S100β as a predictor of brain metastases: brain versus cerebrovascular damage. Cancer104(4), 817–824 (2005).
   PubMedGoogle Scholar
• Staner L. Surrogate outcomes in neurology, psychiatry, and psychopharmacology. Dialogues Clin. Neurosci.8(3), 345–352 (2006).
   PubMedGoogle Scholar
• Engelter ST, Provenzale JM, Petrella JR, DeLong DM, Alberts MJ. Infarct volume on apparent diffusion coefficient maps correlates with length of stay and outcome after middle cerebral artery stroke. Cerebrovasc. Dis.15(3), 188–191 (2003).
   PubMedGoogle Scholar
• Ay H, Koroshetz WJ, Vangel M et al. Conversion of ischemic brain tissue into infarction increases with age. Stroke36(12), 2632–2636 (2005).
   PubMed Web of Science ®Google Scholar
• Ay H, Arsava EM, Rosand J et al. Severity of leukoaraiosis and susceptibility to infarct growth in acute stroke. Stroke39(5), 1409–1413 (2008).
   PubMed Web of Science ®Google Scholar
• Menezes NM, Ay H, Wang Zhu M et al. The real estate factor: quantifying the impact of infarct location on stroke severity. Stroke38(1), 194–197 (2007).
   PubMedGoogle Scholar
• Wu O, Koroshetz WJ, Ostergaard L et al. Predicting tissue outcome in acute human cerebral ischemia using combined diffusion- and perfusion-weighted MR imaging. Stroke32(4), 933–942 (2001).
   PubMed Web of Science ®Google Scholar
• Thijs VN, Somford DM, Bammer R, Robberecht W, Moseley ME, Albers GW. Influence of arterial input function on hypoperfusion volumes measured with perfusion-weighted imaging. Stroke35(1), 94–98 (2004).
   PubMed Web of Science ®Google Scholar
• Schiemanck SK, Kwakkel G, Post MW, Kappelle LJ, Prevo AJ. Predicting long-term independency in activities of daily living after middle cerebral artery stroke: does information from MRI have added predictive value compared with clinical information? Stroke37(4), 1050–1054 (2006).
   PubMed Web of Science ®Google Scholar
• Schiemanck SK, Kwakkel G, Post MW, Prevo AJ. Predictive value of ischemic lesion volume assessed with magnetic resonance imaging for neurological deficits and functional outcome poststroke: a critical review of the literature. Neurorehabil. Neural Repair20(4), 492–502 (2006).
   PubMed Web of Science ®Google Scholar
• Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke40(5), e380–389 (2009).
   PubMed Web of Science ®Google Scholar
• Hlatky MA, Greenland P, Arnett DK et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation119(17), 2408–2416 (2009).
   PubMed Web of Science ®Google Scholar
• Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat. Med.16(9), 965–980 (1997).
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat. Med.27(2), 157–172; discussion 207–112 (2008).
   PubMed Web of Science ®Google Scholar